Α‐Galactosidase A‐deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease. Issue 1 (6th July 2018)

• Record Type: Journal Article
• Authors: Miller, James J.; Aoki, Kazuhiro; Mascari, Carly A.; Beltrame, Angela K.; Sokumbi, Olayemi; North, Paula E.; Tiemeyer, Michael; Kriegel, Alison J.; Dahms, Nancy M.
• Is Part Of: FASEB journal. Volume 33:Issue 1(2019)
• Page Start: 418
• Page End: 429
• Publication Date: 2018-07-06
• Subjects: lysosomal storage disease -- glycobiology -- kidney -- heart -- animal model; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201800771R
• Languages: English
• ISSNs: 0892-6638

Abstract

ABSTRACT: Fabry disease is an X‐linked lysosomal storage disease caused by α‐galactosidase A (α‐Gal A) deficiency. Kidney and heart failure are frequent complications in adulthood and greatly contribute to patient morbidity and mortality. Because α‐Gal A‐deficient mouse models do not recapitulate cardiorenal findings observed in patients, a nonmouse model may be beneficial to our understanding of disease pathogenesis. In this study, we evaluated disease processes in a recently generated Fabry rat model. We found that male Fabry rats weighed significantly less than wild‐type (WT) males, whereas female Fabry rats weighed significantly more than WT females. Whereas no difference in female survival was detected, we observed that male Fabry rats had a decreased lifespan. Skin histology revealed that inflammation and lipoatrophy may be chief disease mediators in patients. With respect to the kidney and heart, we found that both organs accumulate α‐Gal A substrates, including the established biomarkers, globotriaosylceramide and globotriaosylsphingosine. Longitudinal serum and urine chemistry panels demonstrated pronounced renal tubule dysfunction, which was confirmed histologically. Mitral valve thickening was observed in Fabry rats using echocardiography. We conclude that Fabry rats recapitulate important kidney and heart phenotypes experienced by patients and can be further used to study disease mechanisms and test therapies.—Miller, J. J., Aoki, K., Mascari, C. A., Beltrame, A. K., Sokumbi, O., North, P. E., Tiemeyer, M., Kriegel, A. J., Dahms, N. M., α‐Galactosidase A‐deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease. FASEB J. 33, 418–429 (2019). www.fasebj.org